Endologix and TriVascular Technologies to merge companies and endovascular abdominal aortic aneurysm treatments

Endologix and TriVascular Technologies announced that they have entered into a definitive merger agreement under which Endologix and TriVascular will combine in a stock and cash transaction. John McDermott, Chairman and Chief Executive Officer of Endologix, said, "We believe the combined company will be uniquely positioned to provide physicians with three complementary products to treat a wide range of patient anatomies. These devices, the AFX, Ovation and Nellix systems each offer unique clinical advantages and together will offer physicians the ability to choose the best solution for each patient – all provided by one company". In addition to the existing products, the combined company will have a pipeline of new devices including AFX2 and the Ovation iX system that are both planned for market introduction by the first quarter of 2016. These new products are expected to be followed by additional new technologies including the launch of Nellix in the US, which is expected to receive PMA approval by the end of 2016. TriVascular will survive the merger as a wholly-owned subsidiary of Endologix.